Asahi Kasei Pharma
VC Fund
Tokyo, Japan
Asahi Kasei Pharma is a VC fund in Tokyo focused on Biotechnology and Medical. Asahi Kasei Pharma is growing as a specialty pharmaceutical firm with a global presence by focusing on the development of new world-class drugs in selected therapeutic fields. In diagnostics, management resources are concentrated on products with strong growth prospects.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Asahi Kasei Pharma invests in
Stages Asahi Kasei Pharma invests in
Countries Asahi Kasei Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dalton Einhorn
|
|||
Investment Focus
Industry
- Biotechnology 4 (80%)
- Medical 3 (60%)
- Health Care 3 (60%)
- Analytics 1 (20%)
- Therapeutics 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series C 1 (20%)
Country
- Japan 2 (40%)
- United States 1 (20%)
- United Kingdom 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dalton Einhorn
Director New Pharma Ventures
|
Director New Pharma Ventures | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mediar Therapeutics
|
Mediar Therapeutics is a biotechnology company that develops antibody-based medicines and biologic therapies to address cancer, autoimmune diseases, and other serious health conditions. Its research platform focuses on engineering multi-specific antibodies and modular biologics that can engage multiple biological targets or pathways simultaneously,enabling precise modulation of immune responses. The company’s pipeline includes therapeutic candidates designed to activate or inhibit specific immune functions, with the goal of improving clinical outcomes in oncology and immune-mediated disorders. Mediar Therapeutics also works on scalable manufacturing processes and collaborates with scientific partners to advance its biologics from discovery through clinical development. Its approach integrates protein engineering, immunology, and translational research to create biologic medicines that address complex disease mechanisms. The company continues to refine its technology and expand its therapeutic programs to support future clinical and regulatory progress. | $76M / Series B / Jan 07, 2026 | |
Curreio
|
Curreio develops contract business for structural analysis using cryo-electron microscopy. | Series A / Mar 20, 2023 | |
LUCA Science
|
LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M / Series B / Jun 06, 2022 | |
|
Curreio
|
Curreio develops contract business for structural analysis using cryo-electron microscopy. | Series A / Jun 23, 2021 | |
Pulmocide
|
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $92M / Series C / May 27, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Asahi Kasei Pharma invest in?
Asahi Kasei Pharma invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Asahi Kasei Pharma?
Public channels for Asahi Kasei Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Asahi Kasei Pharma?
The team at Asahi Kasei Pharma includes Dalton Einhorn (Director New Pharma Ventures). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
